Axsome Therapeutics(US:AXSM) Financial Modeling Prep·2026-01-08 06:00Company Overview - Axsome Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies for central nervous system disorders, particularly for conditions like depression and migraines [1] - The company is recognized for its innovative drug pipeline and strategic partnerships in a competitive landscape [1] Recent Transactions - On January 7, 2026, CEO Herriot Tabuteau sold 31,261 shares at $170.38 each, reducing his holdings to 7,229 shares [2] - Director Mark Saad sold 37,577 shares at $165.18 each on December 31, 2025, decreasing his ownership by 78.98% to 10,002 shares [2][5] Stock Performance - Axsome's stock opened at $178.69 and is currently priced at $170.69, reflecting a slight decrease of 0.69% [3] - The stock has traded between $168.02 and $173.73 recently, with a yearly low of $79.19 and a high of $184.40, indicating significant volatility [3] Financial Metrics - The company has a market capitalization of approximately $8.60 billion [4][5] - Axsome has a negative price-to-earnings (P/E) ratio of -38.26, while the price-to-earnings-growth ratio is at 16.17 [4] - Financial health indicators include a debt-to-equity ratio of 1.66, a quick ratio of 1.50, and a current ratio of 1.57, suggesting a stable liquidity position [4]